Inicio / Hematología / Abstracts de hematología / Outcomes of patients with…

Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study

0 / 5 (0 votos)
Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study

The Lancet Haematology

Fecha de publicación: 1 de febrero de 2021

DOI: https://doi.org/10.1016/S2352-3026(20)30374-4

Autores: Lisa Pleyer, MD, Michael Leisch, MD, Alexandra Kourakli, MD, Eric Padron, MD, Jaroslaw Pawel Maciejewski, MD, Blanca Xicoy Cirici, PhD, Jennifer Kaivers, MD, Johanna Ungerstedt, MD, Sonja Heibl, MD, Peristera Patiou, MSc, Anthony Michael Hunter, MD, Elvira Mora, MD, Prof Klaus Geissler, MD, Maria Dimou, MD, Maria-José Jimenez Lorenzo, MD, Thomas Melchardt, MD, Prof Alexander Egle, MD, Athina-Nora Viniou, MD, Bhumika Jayantibhai Patel, MD, Montserrat Arnan, PhD, Peter Valent, MD, Christoforos Roubakis, MD, Teresa Bernal del Castillo, MD, Athanasios Galanopoulos, MD, Marisa Calabuig Muñoz, MD, Nicolas Bonadies, MD, Antonio Medina de Almeida, PhD, Prof Jaroslav Cermak, PhD, Andrés Jerez, PhD, Maria Julia Montoro, MD, Albert Cortés, MD, Alejandro Avendaño Pita, MD, Bernardo Lopez Andrade, MD, Prof Eva Hellstroem-Lindberg, MD, Prof Ulrich Germing, MD, Mikkael Aaron Sekeres, MD, Alan Francis List, MD, Prof Argiris Symeonidis, MD, Guillermo Francisco Sanz, MD, Julian Larcher-Senn, PhD, Prof Richard Greil, MD

Background: Approval of hypomethylating agents in patients with chronic myelomonocytic leukaemia is based on trials done in patients with myelodysplastic syndromes. We aimed to investigate whether hypomethylating agents provide a benefit in subgroups of patients with chronic myelomonocytic leukaemia compared with other treatments.

Leer más

Comentarios

Para dejar un comentario antes debes iniciar sesión:

¿No tienes una cuenta?

Regístrate a través de éste enlace.